GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (MEX:ATOS) » Definitions » E10

Atossa Therapeutics (MEX:ATOS) E10 : MXN-662.73 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Atossa Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Atossa Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was MXN-1.043. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN-662.73 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was 22.70% per year. During the past 5 years, the average E10 Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Atossa Therapeutics was 22.70% per year. The lowest was 5.20% per year. And the median was 13.60% per year.

As of today (2025-03-28), Atossa Therapeutics's current stock price is MXN15.13. Atossa Therapeutics's E10 for the quarter that ended in Dec. 2024 was MXN-662.73. Atossa Therapeutics's Shiller PE Ratio of today is .


Atossa Therapeutics E10 Historical Data

The historical data trend for Atossa Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics E10 Chart

Atossa Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1,289.68 -1,078.38 -681.69 -662.73

Atossa Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -681.69 -667.00 -718.41 -650.67 -662.73

Competitive Comparison of Atossa Therapeutics's E10

For the Biotechnology subindustry, Atossa Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Shiller PE Ratio falls into.


;
;

Atossa Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atossa Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.043/133.1571*133.1571
=-1.043

Current CPI (Dec. 2024) = 133.1571.

Atossa Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201503 -356.733 99.621 -476.822
201506 -310.666 100.684 -410.864
201509 -474.498 100.392 -629.364
201512 -418.872 99.792 -558.918
201603 -202.437 100.470 -268.297
201606 -148.688 101.688 -194.702
201609 16.242 101.861 21.232
201612 -178.132 101.863 -232.858
201703 -1,220.124 102.862 -1,579.474
201706 -139.547 103.349 -179.795
201709 -38.292 104.136 -48.964
201712 -14.760 104.011 -18.896
201803 -154.061 105.290 -194.837
201806 -99.819 106.317 -125.019
201809 -11.971 106.507 -14.966
201812 4.123 105.998 5.179
201903 -12.027 107.251 -14.932
201906 -15.367 108.070 -18.934
201909 -7.107 108.329 -8.736
201912 -4.904 108.420 -6.023
202003 -7.503 108.902 -9.174
202006 -9.925 108.767 -12.151
202009 -7.511 109.815 -9.108
202012 -17.505 109.897 -21.210
202103 -0.818 111.754 -0.975
202106 -1.194 114.631 -1.387
202109 -0.822 115.734 -0.946
202112 -0.821 117.630 -0.929
202203 -0.796 121.301 -0.874
202206 -1.060 125.017 -1.129
202209 -1.207 125.227 -1.283
202212 -1.170 125.222 -1.244
202303 -0.901 127.348 -0.942
202306 -1.372 128.729 -1.419
202309 -0.871 129.860 -0.893
202312 -1.018 129.419 -1.047
202403 -0.830 131.776 -0.839
202406 -0.916 132.554 -0.920
202409 -1.181 133.029 -1.182
202412 -1.043 133.157 -1.043

Add all the adjusted EPS together and divide 10 will get our e10.


Atossa Therapeutics  (MEX:ATOS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Atossa Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Atossa Therapeutics Business Description

Traded in Other Exchanges
Address
107 Spring Street, Seattle, WA, USA, 98104
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Headlines